These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23829613)

  • 1. Rethinking cancer vaccines to avoid T-cell traps.
    Peoples GE
    Immunotherapy; 2013 Jul; 5(7):665-8. PubMed ID: 23829613
    [No Abstract]   [Full Text] [Related]  

  • 2. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
    Schaed SG; Klimek VM; Panageas KS; Musselli CM; Butterworth L; Hwu WJ; Livingston PO; Williams L; Lewis JJ; Houghton AN; Chapman PB
    Clin Cancer Res; 2002 May; 8(5):967-72. PubMed ID: 12006508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
    Harris RC; Chianese-Bullock KA; Petroni GR; Schaefer JT; Brill LB; Molhoek KR; Deacon DH; Patterson JW; Slingluff CL
    J Immunother; 2012 Jan; 35(1):78-88. PubMed ID: 22130163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
    Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
    Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
    Slingluff CL; Petroni GR; Smolkin ME; Chianese-Bullock KA; Smith K; Murphy C; Galeassi N; Neese PY; Grosh WW; Nail CJ; Ross M; von Mehren M; Haas N; Boisvert ME; Kirkwood JM
    J Immunother; 2010; 33(6):630-8. PubMed ID: 20551833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer. Fusion potential for vaccines.
    Taylor-Papadimitriou J; Balkwill F
    Nature; 1993 Apr; 362(6422):695. PubMed ID: 8469278
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer.
    Yamamoto K; Ueno T; Kawaoka T; Hazama S; Fukui M; Suehiro Y; Hamanaka Y; Ikematsu Y; Imai K; Oka M; Hinoda Y
    Anticancer Res; 2005; 25(5):3575-9. PubMed ID: 16101182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.
    Huijbers EJ; Femel J; Andersson K; Björkelund H; Hellman L; Olsson AK
    Vaccine; 2012 Jan; 30(2):225-30. PubMed ID: 22079080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Getting melanoma cells to stimulate with frequency.
    Carson WE
    J Clin Oncol; 2005 Dec; 23(35):8929-31. PubMed ID: 16260688
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.
    Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
    J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development.
    Eggermont AM
    Clin Cancer Res; 2009 Nov; 15(22):6745-7. PubMed ID: 19903779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
    Laurent J; Speiser DE; Appay V; Touvrey C; Vicari M; Papaioannou A; Canellini G; Rimoldi D; Rufer N; Romero P; Leyvraz S; Voelter V
    J Immunother; 2010 Sep; 33(7):723-34. PubMed ID: 20664354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
    Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
    Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proposal for a simple and inexpensive therapeutic cancer vaccine.
    Fahrer AM
    Immunol Cell Biol; 2012 Mar; 90(3):310-3. PubMed ID: 21606943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calling cancer's bluff with neoantigen vaccines.
    DeWeerdt S
    Nature; 2017 Dec; 552(7685):S76-S77. PubMed ID: 29293229
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
    Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
    J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
    Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
    Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DC-based cancer vaccines: lessons from clinical trials.
    Brody JD; Engleman EG
    Cytotherapy; 2004; 6(2):122-7. PubMed ID: 15203988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.